IP Library Granted Patent US 8,563,698
Granted Patent B2
US 8,563,698 · App. 12/474,176 · Granted Oct 22, 2013

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)

Inventors: Simon Mark Jackson (San Carlos, CA); Nigel Pelham Clinton Walker (Burlingame, CA); Derek Evan Piper (Santa Clara, CA); Wenyan Shen (Palo Alto, CA); Chadwick Terence King (North Vancouver, CA); Randal Robert Ketchem (Snohomish, WA); Christopher Mehlin (Seattle, WA); Teresa Arazas Carabeo (New York, NY)
Assignee: Amgen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,698
App. No.
12/474,176
Granted
Oct 22, 2013
Kind
B2
Abstract

Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Claims (6)

1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123-132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9's inhibition of cellular LDL uptake.

2. The isolated monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises a humanized or human antibody.

3. The isolated monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises a full length monoclonal antibody.

4. The isolated monoclonal antibody of claim 3 , wherein said monoclonal antibody is of the IgG4- or the IgG2-type.

5. A pharmaceutical composition comprising the monoclonal antibody of claim 1 .

6. The isolated monoclonal antibody of claim 1 , wherein the monoclonal antibody is an immunologically functional fragment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2012
From: JACKSON, SIMON M.; WALKER, NIGEL PELHAM CLINTON; PIPER, DEREK EVAN; SHAN, BEI; SHEN, WENYAN; CHAN, JOYCE CHI YEE; KING, CHADWICK TERENCE; KETCHEM, RANDAL ROBERT; MEHLIN, CHRISTOPHER; CARABEO, TERESA ARAZAS; CAO, QIONG
To: AMGEN INC.
Reel/Frame 028372/0946 →
Continuity (6)
Continuation 12197093 · Aug 22, 2008
Provisional Application 60957668 · Aug 23, 2007
Provisional Application 61008965 · Dec 21, 2007
Provisional Application 61010630 · Jan 9, 2008
Provisional Application 61086133 · Aug 4, 2008
Related Publication 20090326202A1 · Dec 31, 2009